HUDCOVÁ, Kristýna, Martina RAUDENSKÁ, Jaromír GUMULEC, Hana BINKOVA, Zuzana HORAKOVA, Rom KOSTRICA, Petr BABULA, Vojtech ADAM and Michal MASAŘÍK. Expression profiles of miR-29c, miR-200b and miR-375 in tumour and tumour-adjacent tissues of head and neck cancers. Tumor Biology. Dordrecht: Springer, 2016, vol. 37, No 9, p. 12627-12633. ISSN 1010-4283. Available from: https://dx.doi.org/10.1007/s13277-016-5147-2.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Expression profiles of miR-29c, miR-200b and miR-375 in tumour and tumour-adjacent tissues of head and neck cancers
Authors HUDCOVÁ, Kristýna (203 Czech Republic, belonging to the institution), Martina RAUDENSKÁ (203 Czech Republic, belonging to the institution), Jaromír GUMULEC (203 Czech Republic, belonging to the institution), Hana BINKOVA (203 Czech Republic), Zuzana HORAKOVA (203 Czech Republic), Rom KOSTRICA (203 Czech Republic), Petr BABULA (203 Czech Republic, belonging to the institution), Vojtech ADAM (203 Czech Republic) and Michal MASAŘÍK (203 Czech Republic, guarantor, belonging to the institution).
Edition Tumor Biology, Dordrecht, Springer, 2016, 1010-4283.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Germany
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.650
RIV identification code RIV/00216224:14110/16:00088428
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1007/s13277-016-5147-2
UT WoS 000387075400102
Keywords in English Head and neck neoplasms; Carcinoma; squamous cell of head and neck; MicroRNAs; Biomarkers; tumour; Survival; Proportional hazards models
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 10/1/2017 10:45.
Abstract
Altered expression of microRNAs (miRNAs) has been shown in many types of malignancies including the head and neck squamous cell carcinoma (HNSCC). Although there are many new and innovative approaches in the treatment of HNSCC, a clear marker of this disease is still missing. Three candidate miRNAs (miR-29c-3p, miR-200b-5p and miR-375-3p) were studied in connection with HNSCC using quantitative real-time PCR expression levels in 42 tissue samples of HNSCC patients and histologically normal tumour-adjacent tissue samples of these patients. Primary HNSCC carcinoma tissues can be distinguished from histologically normal-matched noncancerous tumour-adjacent tissues based on hsa-miR-375-3p expression (sensitivity 87.5 %, specificity 65 %). Additionally, a significant decrease of hsa-miR-200b-5p expression was revealed in tumour-adjacent tissue samples of patients with node positivity. Lower expression of hsa-miR-200b-5p and hsa-miR-29c-3p in HNSCC tumour tissue was associated with higher tumour grade. Consequently, survival analysis was performed. Lower expression of hsa-miR-29c-3p in tumour-adjacent tissue was associated with worse overall and disease-specific survivals. Lower expression of miR-29c-3p in tumourous tissue was associated with worse relapse-free survival. hsa-miR-375-3p seems to be a relatively promising diagnostic marker in HNSCC but is not suitable for prognosis of patients. Furthermore, this study highlighted the importance of histologically normal tumour-adjacent tissue in HNSCC progress (significant decrease of hsa-miR-200b-5p expression in tumour-adjacent tissue of patients with node positivity and low expression of hsa-miR-29c-3p in HNSCC tumour-adjacent tissue associated with worse prognosis).
Links
GA16-12454S, research and development projectName: Charakterizace a modifikace komplexní odpovědi buněk nádorů hlavy a krku na různá záření - krok kupředu ke kombinované personalizované (radio)terapii
Investor: Czech Science Foundation
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/1365/2015, interní kód MUName: Kardiovaskulární systém: od modelu přes terapii k prevenci (Acronym: KAMOTEPRE)
Investor: Masaryk University, Category A
MUNI/A/1426/2015, interní kód MUName: Genetická a epigenetická patofyziologie vybraných stavů (Acronym: Genetika a epigenetika)
Investor: Masaryk University, Category A
NV16-29835A, research and development projectName: Molekulárně-genetické markery predikce účinnosti radioterapie u nádorů hlavy a krku
PrintDisplayed: 26/8/2024 16:12